Search bioRxiv⌕ Search

Biology subjects

Reig, B.

Publications and source records attributed to Reig, B..

2 recordsLinked to original sources

Impact of Ethylene Oxide Sterilization on PEDOT:PSS Electrophysiology Electrodes

Poly(3,4-ethylenedioxythiophene):polystyrene sulfonate (PEDOT:PSS) is widely used to fabricate conductive organic coatings for electrodes in electrophysiology. As these devices move toward clinical translation, establishing sterilization methods that preserve their functional properties is essential. Ethylene oxide (EtO) is routinely used for sterilizing heat- and moisture-sensitive medical devices due to its high penetration efficiency and low thermal load. However, the absence of systematic studies evaluating its impact on PEDOT:PSS raises concerns about the compatibility of EtO sterilization with organic electrophysiology interfaces. Here, we report the first comprehensive evaluation of EtO sterilization on PEDOT:PSS electrodes electrochemically deposited onto cortical interfaces designed for intraoperative monitoring and stimulation. EtO exposure induced only minimal changes in surface topography, with no detectable alteration of the electrical or electrochemical performance of the electrodes. Impedance spectroscopy, cyclic voltammetry, and charge-injection capacity measurements all revealed that EtO-treated electrodes retained properties comparable to untreated controls. Moreover, EtO-sterilized PEDOT:PSS coatings demonstrated robust long-term stability under accelerated lifetime testing, exhibiting negligible degradation over extended operation. These findings demonstrate that EtO sterilization is fully compatible with PEDOT:PSS-based bioelectronic interfaces and constitutes a viable pathway toward their safe and effective integration into clinical electrophysiology. This work represents an important step toward translating organic conducting polymer technologies into real-world biomedical applications.

bioengineering↗

Mosaicism of BRAF V600E in Healthy Skin Predicts Neurodegeneration in Histiocytosis

Most histiocytoses harbor an oncogenic somatic alteration activating the MAP kinase pathway, the most frequent of which is BRAFV600E. Targeted therapy with BRAF or MEK inhibitors is highly effective, but neurodegeneration remains a severe complication. Recent data suggest that neurodegeneration may be secondary to mosaicism for BRAFV600E in microglia. In the prospective observational TARGET-HISTIO cohort study, we investigated extra-CNS mosaicism of BRAFV600E in a cohort of 124 adults with histiocytosis. Seeking widespread mosaicism, we analyzed healthy skin biopsies from areas without histiocytosis or melanocytic infiltration using high-sensitivity digital polymerase chain reaction. BRAFV600Ewas detected in healthy skin in 57/67 (85%) patients with BRAFV600Ehistiocytosis and was present in all second and third skin biopsies (n=6). BRAFV600Ewas absent from skin biopsies in all 37 patients with histiocytosis harboring another oncogenic mutation. BRAFV600E was also present in skin biopsies of four /20 patients with histiocytosis of unknown molecular status. Cells harboring BRAFV600E share characteristics with resident dermis macrophages. Only 58% of patients with BRAFV600E in skin also had BRAFV600E in blood leukocytes. Variant allele frequency in skin and blood leukocytes was 16 times lower than in histiocytosis, and frequency in skin was independent of treatment with BRAF/MEK inhibitors. None of the patients with wild type BRAF alleles in skin had neurodegeneration, whereas 22/61 (36%) of patients with BRAFV600E in skin had neurodegeneration. This study demonstrates that mosaicism of BRAFV600Ein healthy skin is frequent in patients with histiocytosis and is strongly associated with neurodegeneration. Key PointsLow allele frequency of the oncogene BRAF V600E is frequent in healthy skin of patients with histiocytosis. Patients without BRAF V600E in skin do not develop neurodegeneration, while 36% of those with BRAF V600E mosaicism do.

cancer biology↗